Woori Venture Partners
VC Fund
Seongnam, South Korea
Woori Venture Partners is an investment firm.
- Total investments:
- 64
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries Woori Venture Partners invests in
Stages Woori Venture Partners invests in
Countries Woori Venture Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $2.9M–$33M
- Series B
- $4.8M–$73M
- Series C
- $3.5M–$122M
Investment Focus
Industry
- Artificial Intelligence 15 (23%)
- Software 12 (19%)
- Biotechnology 10 (16%)
- Pharmaceutical 8 (13%)
- Health Care 7 (11%)
Stage
- Series A 19 (30%)
- Series B 16 (25%)
- Series C 9 (14%)
- Seed 6 (9%)
- Venture - Series Unknown 5 (8%)
Country
- South Korea 42 (66%)
- United States 5 (8%)
- Singapore 4 (6%)
- India 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Choi Hyung-seok
Team Leader
|
Team Leader | Total investments: 1 | Find email | |
|
Kim Man-sik
Team Leader
|
Team Leader | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Prazer Therapeutics
|
Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $33.9M / Venture - Series Unknown / Jul 23, 2026 | |
ArcGen Bioscience
|
ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M / Series A / Jul 13, 2026 | |
PROMEDIUS
|
Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $14M / Series B / Jun 05, 2026 | |
Unastella
|
Unastella is an aerospace company developing human spaceflight technologies, including launch vehicles and suborbital tourism systems. The company focuses on advancing reusable rocket technology and future space travel infrastructure for civilian space exploration missions. Unastella aims to support the growth of private human spaceflight andnext-generation aerospace innovation. | $22.2M / Series B / Jun 01, 2026 | |
Upstage
|
Upstage AI develops artificial intelligence technologies focused on large language models and document processing systems designed to support enterprise workflows. Its platform includes tools that convert unstructured data such as PDFs, scans, and emails into structured, machine-readable formats, enabling downstream analysis and automation. Thecompany also provides models like its Solar LLM, which are optimized for tasks such as text generation, information extraction, and question answering within business environments. Its solutions are applied across industries including finance, healthcare, insurance, and manufacturing to handle tasks like document parsing, data extraction, and workflow automation. Additionally, its services can be deployed through APIs, cloud environments, or on-premise systems to integrate with existing enterprise infrastructure. | $380.2M / Venture - Series Unknown / May 03, 2026 | |
|
Upstage
|
Upstage AI develops artificial intelligence technologies focused on large language models and document processing systems designed to support enterprise workflows. Its platform includes tools that convert unstructured data such as PDFs, scans, and emails into structured, machine-readable formats, enabling downstream analysis and automation. Thecompany also provides models like its Solar LLM, which are optimized for tasks such as text generation, information extraction, and question answering within business environments. Its solutions are applied across industries including finance, healthcare, insurance, and manufacturing to handle tasks like document parsing, data extraction, and workflow automation. Additionally, its services can be deployed through APIs, cloud environments, or on-premise systems to integrate with existing enterprise infrastructure. | $121.7M / Series C / Apr 15, 2026 | |
BreezeBio
|
GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $60M / Series B / Feb 25, 2026 | |
BOS Semiconductors
|
BOS Semiconductors is a fabless semiconductor firm specializing in automotive-grade System-on-Chip (SoC) solutions and high-performance computing platforms. Its technologies support advanced driver assistance, autonomous driving, and centralized in-vehicle computing systems. | $60.3M / Series A / Feb 23, 2026 | |
Orum Therapeutics
|
Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M / Post-IPO Equity / Dec 18, 2025 | |
Share It
|
Share It is an IT social network platform that offers space mediation services for idle schools. | $5.4M / Series C / Dec 02, 2025 | |
| See all 64 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Woori Venture Partners invest in?
Woori Venture Partners invests primarily in Artificial Intelligence, Software and Biotechnology startups, most often at Series A and Series B stage. Most of the 64 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Woori Venture Partners's check size?
Woori Venture Partners typically joins rounds of $2.9M–$33M at Series A, $4.8M–$73M at Series B and $3.5M–$122M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Woori Venture Partners participates in.
How do I contact Woori Venture Partners?
Public channels for Woori Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Woori Venture Partners?
The team at Woori Venture Partners includes Choi Hyung-seok (Team Leader) and Kim Man-sik (Team Leader). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
